Novavax Appoints GSK's Bob Darius SVP Quality Operations
This article was originally published in Scrip
Executive Summary
Vaccine company Novavax Inc. has appointed Bob Darius senior vice president of quality operations. Darius was previously vice president of quality operations at GlaxoSmithKline Biologicals and most recently transitioned to head quality advocacy liaison. He also held various positions of increasing responsibility at the FDA's Center for Biologics Evaluation and Research, where he was a senior reviewer and inspector and advisor to the deputy center director of medicine on counter-bioterrorism products.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.